 |
|
AIDS Serology Testing in Low- and High-Risk Groups
James R. Carlson, PhD;
Martin L. Bryant, MD, PhD;
Steven H. Hinrichs, MD;
Janet K. Yamamoto, PhD;
Norman B. Levy, MD;
JoAnn Yee;
Joanne Higgins;
Alexandra M. Levine, MD;
Paul Holland, MD;
Murray B. Gardner, MD;
Niels C. Pedersen, DVM, PhD
JAMA. 1985;253(23):3405-3408.
Abstract
| |
The performance characteristics of the acquired immunodeficiency syndrome (AIDS)—retrovirus serological tests including enzyme-linked immunosorbent assay (ELISA), Western blot, and immunofluorescence assay were defined in a clinical laboratory setting by testing 1,257 serum specimens from low- and high-risk groups for AIDS. The three prototype AIDS retroviruses (lymphadenopathy-associated virus, human T-lymphotropic virus III, and AIDS-associated retrovirus) were equally suitable as target antigen for these assays. Sera from six of 74 laboratory and health care personnel and 91 of 1,014 unselected blood donors were falsely positive by ELISA (positive to negative ratio [P/N],  2) based on the lack of Western blot confirmation. Only two true-positives (two [0.2%] of 1,014 blood donors) were detected in these low-risk groups. In contrast, 106 of 108 specimens with ELISA P/N ratios of 2 or greater from the high-risk groups including asymptomatic homosexual men, hemophiliacs, AIDS-related complex patients, and AIDS patients were positive by Western blot and immunofluorescence assay. Four false-negative ELISA results based on positive immunofluorescence assay and Western blot were found in the AIDS patient group. Ten of 69 AIDS patients were negative by all three serological tests. The consequence of maintaining high sensitivity for the ELISA (P/N ratio, 2) as a screening test was a loss of specificity. The number of false-positive results necessitated the use of a confirmation test with greater specificity.
(JAMA 1985;253:3405-3408)
Author Affiliations
From the Departments of Medical Pathology (Drs Carlson, Bryant, Hinrichs, Yamamoto, Levy, and Gardner and Ms Yee) and Veterinary Medicine (Dr Pedersen and Ms Higgins), University of California, Davis; the Department of Medicine, Kenneth Norris Jr Cancer Center, University of Southern California, Los Angeles (Dr Levine); and the Sacramento (Calif) Medical Foundation Blood Center (Dr Holland).
Footnotes
Reprint requests to Department of Medical Pathology, Room 3453, MSI-A, School of Medicine, University of California, Davis, CA 95616 (Dr Carlson).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Hepatitis B Surface Antigen (HBsAg) Assays--Are They Good Enough for Their Current Uses?
Dufour
Clin. Chem. 2006;52:1457-1459.
FULL TEXT
Classifying Binormal Diagnostic Tests Using Separation - Asymmetry Diagrams with Constant-performance Curves
Somoza
Med Decis Making 1994;14:157-168.
ABSTRACT
Risk Factors for Hepatitis C Virus Seropositivity in Heterosexual Couples
Osmond et al.
JAMA 1993;269:361-365.
ABSTRACT
Successful Use of Pooled Sera to Estimate HIV Antibody Seroprevalence and Eliminate All Positive Cases
Ko et al.
Asia Pac J Public Health 1992;6:146-149.
ABSTRACT
HIV Infection, Pregnant Women, and Newborns: A Policy Proposal for Information and Testing
Working Group on HIV Testing of Pregnant Women and
JAMA 1990;264:2416-2420.
ABSTRACT
Performance Characteristics of Serologic Tests for Human Immunodeficiency Virus Type 1 (HIV-1) Antibody among Minnesota Blood Donors: Public Health and Clinical Implications
MacDonald et al.
ANN INTERN MED 1989;110:617-621.
ABSTRACT
Human Immunodeficiency Virus Test Evaluation, Performance, and Use: Proposals to Make Good Tests Better
Schwartz et al.
JAMA 1988;259:2574-2579.
ABSTRACT
Male-to-Female Transmission of Human Immunodeficiency Virus
Padian et al.
JAMA 1987;258:788-790.
ABSTRACT
Screening for HIV Infection: Risks, Benefits, and the Burden of Proof
Barry et al.
J Law Med Ethics 1986;14:259-267.
HTLV-III Antibody Testing in Hong Kong
Chang et al.
JAMA 1986;256:41-41.
ABSTRACT
Containing the AIDS Epidemic
Schram
JAMA 1985;254:2059-2060.
ABSTRACT
|
